title: [Effects of angrographolide on plasma glucose level of experiment diabetic rats and its molecular mechanism].
abstract: OBJECTIVE
  To investigate the effects of angrographolide on plasma glucose level of diabetic rats and its molecular mechanism.
  
  
  METHODS
  The diabetic model rats were established by intraperitoneal injection of streptozotocin (65 mg/kg). Diabetic rats were treated with angrographolide for 2 weeks, then the activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in serum were examined and the expressions of Bcl-2 and Box gene of pancreatic cells were detected.
  
  
  RESULTS
  Compared with model rats, the plasma glucose levels and the serum MDA contents of the angrographolide-treated rats decreased, serum insulin and activity of SOD increased significatantly (P < 0.01). The expression of Bcl-2 was lower in the model group, while the expression was stronger in the treatment group (P < 0.05).
  
  
  CONCLUSIONS
  Angrographolide can inhibit the apoptosis of islet cells and depress plasma glucose level of diabetic rat model. Its mechanism may be associated with the upregulation of the expression of Bcl-2, the increase of the activity of SOD, the decrease of the production of free radicals and lipid eroxidadion.
authors.affiliation: Department of pharmacology, Guilin Medical College, Guilin 541004, China. yp2805795@163.com
authors.forename: Ping
authors.initials: P
authors.lastname: Yang
authors.forename: Shen-Zhou
authors.initials: SZ
authors.lastname: Chen
authors.forename: Sheng-Jun
authors.initials: SJ
authors.lastname: Xiao
authors.forename: Qiao-Yan
authors.initials: QY
authors.lastname: Hou
authors.forename: Ying-Qiong
authors.initials: YQ
authors.lastname: Zhou
authors.forename: Mei
authors.initials: M
authors.lastname: Feng
authors.forename: Li
authors.initials: L
authors.lastname: Li
mesh_terms: D035685:Andrographis / Q000737:chemistry*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007150:Immunohistochemistry; D007328:Insulin / Q000097:blood; D007783:Lactones / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin / Q000008:administration & dosage; D013482:Superoxide Dismutase / Q000097:blood
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D007783:Lactones; D019253:Proto-Oncogene Proteins c-bcl-2; D008315:Malondialdehyde; D013311:Streptozocin; D013482:Superoxide Dismutase